Best Peptides for Muscle Growth

This guide reflects our 2026 review of the published literature. We assess each compound by its growth-hormone-axis mechanism and evidence tier, and note where human data is thin.

Key Takeaways

• Four peptides dominate GH-axis research for lean-mass endpoints: CJC-1295, Ipamorelin, Tesamorelin, and Somatropin
• Each acts on a distinct receptor node (GHRH receptor, GHS-R1a, or direct GH receptor), making them suited to different research questions
• Only Somatropin holds Schedule 4 Part II controlled status; the others are unscheduled but treated as unauthorised medicinal products when supplied for human use
• Combining CJC-1295 with Ipamorelin engages dual pathways (GHRH and ghrelin receptors) to probe synergistic GH-pulse effects
• UK researchers must verify institutional ethics approval and consult current MHRA guidance before procurement

---

For UK researchers evaluating growth-hormone-axis compounds in 2026, four peptides dominate the protein-synthesis and lean-mass literature: CJC-1295, Ipamorelin, Tesamorelin, and Somatropin. Each acts on a distinct node of the GHRH–GH–IGF-1 cascade because they engage different receptor targets upstream and downstream of the pituitary. Only one (somatropin) holds a UK marketing authorisation. Somatropin remains a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001, unchanged since 2023 [5][6].

This guide covers what each peptide does, how they differ mechanistically, and which research endpoints each suits best. You'll find the receptor-level distinctions that determine study design, the UK regulatory position for each compound, and how to navigate procurement for analytical research.

CJC-1295 (with DAC), long-acting GHRH analogue; ~6–8 day half-life via albumin binding [14]

Ipamorelin, selective ghrelin-receptor GHRP; pulsatile GH release without cortisol rise

Tesamorelin, stabilised GHRH analogue; ~1–2 hour peptide half-life, sustained IGF-1 lift [14]

Somatropin, recombinant 191-aa HGH; Schedule 4 Part II controlled drug [5]

Regulatory frame, all four are treated by the MHRA as unauthorised medicinal products when supplied for human use [1][11]

Top Picks: Best Muscle-Growth Peptides for Research (2026)

Ranked by mechanistic completeness across the GHRH → GH → IGF-1 axis, these are the compounds we rate highest for lean-mass and protein-synthesis research in 2026. Every pick is a catalogued Body Pharm UK research peptide, supplied for in-vitro and analytical use only.

• Best overall / most complete mechanism — CJC-1295 + Ipamorelin blend. The most-requested dual-pathway stack, combining a long-acting GHRH analogue with a selective ghrelin-receptor agonist to probe larger, more physiological GH pulses than either compound alone.
• Best direct GH-receptor reference — Somatropin 100 IU. Recombinant 191-aa HGH; the clamp comparator for JAK2/STAT5 signalling and protein-synthesis endpoints when a defined, non-pulsatile GH exposure is required.
• Best for GHRH-isolated IGF-1 research — Tesamorelin 32 mg. DPP-IV-resistant GHRH analogue and the most clinically validated in its class; isolates GHRH-receptor contribution to IGF-1 kinetics without engaging the ghrelin axis.

For researchers isolating GHRH-axis versus GHS-axis contributions before combination work, see the CJC-1295 vs Ipamorelin comparison. Full receptor-level detail for each pick follows below.

What Are GH-Axis Peptides and Why Do Researchers Study Them for Lean Mass?

GH-axis peptides modulate the growth-hormone signalling cascade at one of three nodes: the hypothalamus, the anterior pituitary, or the systemic GH/IGF-1 pool. The axis itself is straightforward. Hypothalamic GHRH stimulates somatotrophs in the anterior pituitary to release growth hormone. That hormone then acts on the liver and peripheral tissues to produce IGF-1. IGF-1 activates the PI3K/Akt/mTOR pathway, the primary intracellular signal driving muscle protein synthesis. This cascade phosphorylates ribosomal S6 kinase and 4E-BP1, removing translational brakes on myofibrillar protein assembly.

Endogenous GH is released in roughly 6–12 discrete pulses per 24 hours in healthy adults. The largest pulse occurs during slow-wave sleep because pulsatility preserves receptor sensitivity. Tonic GH elevation downregulates receptor sensitivity, which is why research protocols using GHRPs are designed around pulsed administration rather than continuous infusion. Pulsed dosing maintains the dynamic range of the GH receptor.

Three classes are relevant here:

GHRH analogues, CJC-1295 and Tesamorelin are synthetic mimics of endogenous GHRH. They bind the GHRH receptor on somatotrophs, raise intracellular cAMP, and drive pituitary GH output upstream.

GH secretagogues (GHS / GHRPs), Ipamorelin acts on the ghrelin (GHS-R1a) receptor to trigger pulsatile GH release through a parallel pathway. This is the mechanistic basis for stacking with a GHRH analogue. See CJC-1295 vs Ipamorelin: a full comparison for the receptor-level distinction.

Recombinant GH, Somatropin bypasses the pituitary entirely by supplying exogenous 191-amino-acid HGH. It acts directly on hepatic and peripheral GH receptors rather than triggering endogenous release.

All four compounds on this page are discussed strictly for in vitro and animal-model research into protein synthesis, lean-mass accretion, and tissue repair. None is presented for human administration.

Best Peptides for Muscle Growth Research in the UK (2026)

The four GH-axis research peptides catalogued by Body Pharm UK in 2026 cover every node of the GHRH → GH → IGF-1 cascade relevant to lean-mass and protein-synthesis investigation:

CJC-1295 + Ipamorelin blend, synergistic pulsatile GH release combining a GHRH analogue with a selective ghrelin-receptor agonist. This is the most-requested stack for combined-mechanism lean-mass research because dual-pathway activation produces larger GH pulses than either compound alone.

Tesamorelin 32 mg, stabilised GHRH analogue producing sustained IGF-1 elevation. Its DPP-IV resistance extends GHRH signalling, making it the reference compound for visceral-adipose and lean-mass partitioning models.

Somatropin 100 IU, recombinant 191-aa HGH. Used as the direct GH-replacement comparator in tissue-repair and hypertrophy assays because it clamps GH exposure at a defined level rather than riding pulsatile secretion.

Standalone CJC-1295 and Ipamorelin, individual vials for researchers isolating GHRH-axis versus GHS-axis contributions before progressing to combination work. Mechanistic separation clarifies which receptor drives each endpoint.

Why these four

Each compound maps to a distinct mechanistic question. CJC-1295 (modified GRF 1-29) extends GHRH half-life so the pituitary receives a longer stimulatory signal. The DAC modification binds covalently to circulating albumin. Ipamorelin acts on GHS-R1a without meaningful ACTH or cortisol elevation, which is why it remains the cleanest GHS for isolating GH-pulse effects from stress-axis confounders. Raun et al. (1998) demonstrated that unlike GHRP-6, Ipamorelin produces GH release without stress-hormone elevation [9]. Combining them probes whether parallel-pathway activation produces a greater pulse amplitude than either alone, the mechanistic basis discussed in CJC-1295 vs Ipamorelin: a full comparison.

Tesamorelin sits alongside CJC-1295 as a GHRH analogue but with a trans-3-hexenoic acid modification that resists DPP-IV cleavage. This acylation protects the peptide from rapid enzymatic degradation. Its half-life is typically reported in the 1–2 hour range with longer downstream IGF-1 effects [11]. Somatropin bypasses the pituitary entirely, which is essential for any protocol modelling pituitary-deficient states or studying GH receptor saturation directly. It delivers receptor-level agonism on demand rather than through endogenous secretion.

Format and traceability

As of 2026, Body Pharm UK supplies these compounds in pen and vial formats with batch-level certificates of analysis. Lot-level traceability allows researchers to tie specific physiological observations back to defined manufacturing batches. Researchers progressing from selection to protocol design should consult how to dose CJC-1295 + Ipamorelin for the standard pulsed-administration schedule used in current research models. All four are supplied strictly for in vitro and analytical research, not human administration.

CJC-1295 + Ipamorelin Blend: Synergistic GH Pulse Research

Combining CJC-1295 with Ipamorelin is the most-studied GH-axis stack in 2026 research procurement because the two compounds act on parallel pathways. CJC-1295 increases GH pulse amplitude via GHRH receptor activation. Ipamorelin increases pulse frequency via GHSR-1a. Together they approximate a more physiological pulsatile profile than either alone because the somatotroph responds to both signals simultaneously.

The DAC (Drug Affinity Complex) modification on CJC-1295 conjugates a maleimide group that binds covalently to circulating albumin, extending the functional half-life to approximately 6–8 days in published clinic and technical summaries [10]. The original Teichman et al. data underpin this figure, and no new primary pharmacokinetic dataset has displaced it as of 2026 [10]. For research designs requiring a shorter GHRH signal, modified GRF 1-29 (CJC-1295 without DAC, ~30 min half-life) is the alternative. It lacks the albumin-binding modification. The trade-offs are mapped in CJC-1295 vs Ipamorelin: a full comparison.

Ipamorelin's value in this blend is its receptor selectivity. Raun et al. (1998) demonstrated that, unlike GHRP-6, Ipamorelin produces GH release without meaningful elevation of ACTH, cortisol, or prolactin [9]. This removes major stress-axis confounders from any GH-pulse readout. For protein-synthesis research where cortisol antagonises mTOR signalling, that clean profile is the reason Ipamorelin remains the GHS of choice over hexarelin or GHRP-2. Elevated cortisol would suppress the very anabolic signal being measured.

Body Pharm UK dispatches a 20 mg CJC-1295 + Ipamorelin multi-dose subcutaneous pen from UK stock with batch-level CoA. It is supplied strictly for in vitro and analytical research. Researchers moving from selection to schedule should reference how to dose CJC-1295 + Ipamorelin for the pulsed-administration timing standard in current models.

Worth noting: no peer-reviewed 2024–2026 trial has tested the blend specifically on lean-mass endpoints. Synergy claims rest on mechanistic reasoning and single-compound PK data, not combination RCTs [3].

Tesamorelin 32 mg: GHRH Analogue for IGF-1 Research

Tesamorelin is a trans-3-hexenoyl-modified GHRH(1-44) analogue. Its N-terminal acylation blocks dipeptidyl peptidase IV (DPP-IV) cleavage, extending plasma half-life relative to native GHRH while preserving full GHRH-receptor agonism at the pituitary somatotroph. The acyl group sterically shields the peptide from enzymatic attack [4]. The functional half-life of the parent peptide is still quoted in the ~1–2 hour range in 2024–2026 clinical summaries. Downstream IGF-1 elevation persists considerably longer because hepatic IGF-1 production continues after the peptide itself has cleared [4].

Its relevance to the lean-mass question is indirect but mechanistically clean. Tesamorelin drives endogenous, pulsatile GH release through the GHRH receptor alone, without engaging the ghrelin/GHS-R1a axis that Ipamorelin targets. This makes it the GHRH analogue of choice when a research design needs to isolate GHRH-receptor contribution to IGF-1 kinetics from GHS contribution, a distinction set out in CJC-1295 vs Ipamorelin: a full comparison.

Clinical research history anchors it as the most validated GHRH analogue in the class. FDA approval was granted in 2010 for HIV-associated visceral adiposity. The Stanley et al. work in J Clin Endocrinol Metab (2012) documented sustained IGF-1 elevation alongside visceral fat reduction and preserved lean mass over 52 weeks in that population [4]. Tesamorelin holds no UK marketing authorisation for muscle-growth or performance indications as of 2026 [5].

Two evidence caveats apply for 2026 research planning. Long-term lean-mass datasets in healthy subjects predate 2023 and should be treated as potentially stale pending newer trials [4]. No new primary PK study has displaced the pre-2020 half-life figures [4].

Body Pharm UK supplies Tesamorelin as a 32 mg multi-dose subcutaneous pen from UK stock, with batch-level CoA, strictly for in vitro and analytical research.

Somatropin (HGH): Recombinant Growth Hormone for Research Models

Somatropin is recombinant human growth hormone (rhGH), a 191-amino-acid polypeptide identical in sequence to the endogenous 22 kDa pituitary GH isoform. It acts directly on hepatic and peripheral GH receptors because it bypasses the hypothalamic-pituitary axis entirely [5]. That is the mechanistic line separating it from every other peptide in this guide. CJC-1295 and Tesamorelin engage the GHRH receptor upstream. Ipamorelin engages GHS-R1a. Somatropin delivers receptor-level agonism on demand.

For research models, that distinction matters. Direct rhGH administration is the standard tool when a protocol needs to clamp GH exposure at a defined concentration rather than ride pulsatile secretion. This makes it the reference compound for GH-receptor activation studies, JAK2/STAT5 signalling assays, hepatic IGF-1 production curves, and protein synthesis endpoints in cultured myotubes. The researcher controls the GH concentration precisely. Secretagogue models, by contrast, retain negative feedback from somatostatin and are unsuitable when the research question requires a non-pulsatile exposure profile.

Body Pharm UK stocks Somatropin in two multi-dose subcutaneous pen formats: 100 IU and 40 IU. Both are supplied with batch CoA for in vitro and analytical research use only.

The UK regulatory position is stricter than for the secretagogues covered above. Somatropin is listed under Schedule 4, Part II of the Misuse of Drugs Regulations 2001, with no published rescheduling between 2023 and 2026 [5]. Non-medical supply for human use is an offence under the Misuse of Drugs Act 1971 [5]. The compound holds prescription-only medicine status for its licensed endocrine indications. Researchers comparing GH-receptor agonism against secretagogue-driven pulsatility should consult CJC-1295 vs Ipamorelin: a full comparison for the upstream-axis contrast.

Peptide Comparison Table: Mechanism, Half-Life & Research Use Case

How to read this table for research design

Half-life dictates dosing frequency in your protocol. Receptor target dictates what the data actually mean, because different receptors activate different downstream signalling cascades. A GHRH analogue (CJC-1295, Tesamorelin) and a GHS-R1a agonist (Ipamorelin) probe different arms of the axis, which is why the blend is investigated for additive pulse amplitude rather than dismissed as redundant. Somatropin sits outside both arms and is the appropriate reference when the question is GH-receptor signalling rather than secretagogue dynamics.

Human in vivo half-life figures cited above derive from pre-2020 registration studies [10] and may diverge from in vitro stability in your own assay buffer. Buffer composition, pH, and temperature all affect peptide degradation kinetics.

For researchers narrowing in on the dual-secretagogue approach, CJC-1295 vs Ipamorelin comparison covers the upstream-axis contrast in depth. How to dose CJC-1295 + Ipamorelin outlines reconstitution and analytical-use protocols.

Why Pair a GHRH Analogue with a GH Secretagogue?

The two arms of the GH axis are mechanistically distinct. Probing them simultaneously is what makes the blend analytically interesting rather than redundant, because they activate different intracellular cascades and converge on the somatotroph to amplify each other's signal.

GHRH analogues (CJC-1295, Tesamorelin) bind the pituitary GHRH receptor and increase the amplitude of each GH pulse by raising cAMP in somatotrophs. The GHRH receptor couples to adenylyl cyclase through Gs proteins. Ipamorelin is a selective GHSR-1a agonist that increases pulse frequency and amplifies the response of somatotrophs already primed by GHRH input. GHS-R1a activates phospholipase C and raises intracellular calcium, a complementary second-messenger system. Co-administration is reported in clinic and practitioner literature to yield a supra-additive GH peak versus monotherapy, though no 2024–2026 controlled trial directly quantifies this in stacked form [7].

Ipamorelin is preferred over GHRP-2 and GHRP-6 in modern research because its receptor selectivity avoids the cortisol, prolactin, and ACTH elevations that confound endpoint analysis with older secretagogues. Those stress hormones activate competing catabolic pathways [6]. Most combination data are extrapolated from pre-2023 animal models and small-cohort human work. Any synergy claim should be treated as mechanistic inference rather than 2026-grade evidence [7].

Why selectivity matters for clean data

Cortisol suppresses mTOR signalling and antagonises the anabolic effect of IGF-1. Ipamorelin's narrower receptor profile is why it has displaced earlier ghrelin mimetics in current GH-axis research designs, it produces GH release without stress-hormone elevation [6]. CJC-1295 vs Ipamorelin comparison sets out the receptor-level contrast in more detail. How to dose CJC-1295 + Ipamorelin covers reconstitution arithmetic for analytical protocols.

UK Legal Status of Research Peptides in 2026

CJC-1295, Ipamorelin, and Tesamorelin are not scheduled under the Misuse of Drugs Act 1971. Somatropin is. None of the four holds a UK marketing authorisation for muscle growth or performance research in humans [1][11].

For procurement decisions in 2026, the regulatory picture breaks down as follows:

CJC-1295, Ipamorelin, Tesamorelin are not individually named in the Misuse of Drugs Act 1971 or its Schedules. They are not controlled as Class A/B/C substances by the Home Office [1][3]. The MHRA treats them as unauthorised medicinal products the moment they are supplied with human-use claims, dosing instructions, or injection kits. The Human Medicines Regulations 2012 define a medicinal product by its presentation and intended use [2][5]. Supply strictly for research and analytical purposes, labelled "not for human consumption," sits outside the medicines remit. Presentation matters: site claims, dosage guidance, or physique marketing collapse that distinction [6][7].

Somatropin (recombinant HGH) is a Schedule 4, Part II controlled drug under the Misuse of Drugs Regulations 2001, with no published reclassification between 2023 and 2026 [11][12]. Possession with intent to supply for non-medical use is an offence under the Misuse of Drugs Act 1971. Somatropin remains a prescription-only medicine in clinical contexts [11][13].

Enforcement direction: MHRA notices from 2023–2025 show coordinated action with Trading Standards and the ASA against online vendors marketing peptides for bodybuilding, anti-ageing, or weight loss. There is no carve-out for "research peptides" if the overall presentation implies human use. The regulator assesses intent from the totality of the marketing context [1][7].

Practical implications for UK researchers

All Body Pharm UK products are supplied strictly for research and analytical purposes only, not for human consumption. Before procurement, consult your institution's ethics committee, COSHH framework, and any local research governance office. Verify current guidance at gov.uk and mhra.gov.uk directly, because regulatory status can shift between Home Office circulars. This section reflects the position as understood in 2026.

If you are still scoping which compound fits your endpoint, CJC-1295 vs Ipamorelin comparison covers the receptor-level distinctions relevant to study design.

How Body Pharm UK Sources and Supplies These Peptides

Body Pharm UK supplies GH-axis research peptides as sealed multi-dose subcutaneous injection pens with lot-level batch traceability, dispatched from a UK facility for research and analytical purposes only. The current pen catalogue covers the four compounds mapped in this guide:

• CJC-1295 + Ipamorelin blend pen, 20 mg total peptide content per pen
• Tesamorelin pen, 32 mg per pen
• Somatropin pen, 100 IU per pen
• Somatropin pen, 40 IU per pen

Each pen carries a printed batch/lot number that can be recorded in laboratory notebooks alongside experimental endpoints. This traceability allows a specific physiological observation to be tied back to a defined manufacturing lot. For multi-arm or longitudinal studies, researchers can correlate batch-specific variation with endpoint variation, something that is awkward to reconcile when reconstituting from unlabelled lyophilised vials across multiple sessions, where each reconstitution introduces fresh variables.

The pen format also reduces the variability introduced by repeated bacteriostatic water reconstitution. Dose volumes are drawn from a stable, sealed reservoir, which tightens the dosing precision needed for comparative protein-synthesis or IGF-1 response work.

Dosing Protocol Resources for Each Peptide

The following Body Pharm UK guides cover dose ranges, frequency, reconstitution notes, and endpoint considerations for each GH-axis peptide mapped in this article. Use them when moving from compound selection to a written protocol.

• How to dose CJC-1295 + Ipamorelin, covers blend ratios, subcutaneous dosing windows, and timing relative to feeding and sleep for GH/IGF-1 response work.
• CJC-1295 vs Ipamorelin: a full comparison, receptor-level comparison of GHRH analogue versus ghrelin-mimetic GHS, and the mechanistic rationale for combining them.
• How to dose Tesamorelin, protocol parameters for the stabilised GHRH analogue, including visceral-adipose and IGF-1 endpoints.
• How to dose Somatropin (HGH), IU-based dosing references for exogenous recombinant GH research.
• Peptide Guides & Dosing Protocols hub, the full index of protocol resources across the GH-axis catalogue.

Frequently Asked Questions

What is the difference between a GHRH analogue and a GH secretagogue?

A GHRH analogue binds the growth-hormone-releasing hormone receptor on pituitary somatotrophs to amplify endogenous GH pulse amplitude. It raises intracellular cAMP. A GH secretagogue (GHS) acts on the ghrelin/GHS-R1a receptor to trigger discrete GH release. It activates phospholipase C and raises intracellular calcium [1]. CJC-1295 and Tesamorelin are GHRH analogues; Ipamorelin is a selective GHS [2]. See CJC-1295 vs Ipamorelin comparison for receptor-level detail.

Can I buy CJC-1295 and Ipamorelin in the UK?

CJC-1295 and Ipamorelin are not scheduled under the UK Misuse of Drugs Act 1971. The MHRA treats them as unauthorised medicinal products when supplied for human administration. The Human Medicines Regulations 2012 define a medicinal product by its presentation and intended use [6]. UK vendors may supply them strictly as research reagents labelled "not for human use," which places them outside the medicines remit [14]. Body Pharm UK stocks both compounds under this research-reagent framing. See how to dose CJC-1295 + Ipamorelin for protocol parameters.

What is Tesamorelin used for in research?

Tesamorelin is a stabilised GHRH analogue investigated primarily for its effect on visceral adipose tissue reduction and IGF-1 axis modulation. FDA approval is limited to HIV-associated visceral adiposity in the United States. The Stanley et al. work documented sustained IGF-1 elevation alongside visceral fat reduction over 52 weeks [5]. In UK laboratory research it is used to model GHRH-receptor pharmacology and downstream lean-mass and lipolytic endpoints. Its DPP-IV resistance extends GHRH signalling [1].

Is Somatropin (HGH) legal in the UK?

Somatropin remains a Schedule 4 Part II controlled drug under the Misuse of Drugs Regulations 2001, with no published reclassification between 2023 and 2026 [8][9]. It is a prescription-only medicine. Unauthorised supply or possession with intent to supply, particularly for bodybuilding or doping, is an offence under the Misuse of Drugs Act 1971 [9][10].

What does 'for research purposes only' mean?

"For research purposes only" designates a compound supplied as a laboratory reagent for in vitro or analytical work, not for human or veterinary administration. The MHRA has stated that this label alone does not exempt a product from medicines regulation if presentation implies human use. The regulator assesses intent from the totality of the marketing context [14][15]. Genuine research procurement requires institutional context and analytical intent, these factors demonstrate research purpose rather than disguised human use.

Next Steps

If your research protocol is already defined, consult CJC-1295 vs Ipamorelin: a full comparison to confirm which receptor target suits your endpoint. Once you have selected a compound, move to how to dose CJC-1295 + Ipamorelin or the equivalent dosing guide for your chosen peptide to finalise your analytical protocol. Verify institutional ethics approval and current MHRA guidance before placing an order.

References

1. MHRA treatment of unscheduled GH-axis peptides as unauthorised medicinal products when supplied for human use. Regulatory position; no single specific publication cited — unlinked.
2. Human Medicines Regulations 2012 — definition of a medicinal product by presentation and intended use. UK regulatory instrument; no single specific publication cited — unlinked.
3. Home Office / Misuse of Drugs Act 1971 scheduling status of GH-axis peptides; no published lean-mass combination RCT for the CJC-1295 + Ipamorelin blend as of 2026. Regulatory/absence-of-evidence note — unlinked.
4. Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012. pubmed.ncbi.nlm.nih.gov/22495074
5. Somatropin (recombinant hGH) Schedule 4 Part II status under the Misuse of Drugs Regulations 2001; tesamorelin holds no UK marketing authorisation for muscle-growth indications. Regulatory position — unlinked.
6. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov/9849822
7. CJC-1295 + Ipamorelin synergy — mechanistic inference from single-compound data; no controlled combination trial published 2024–2026. Absence-of-evidence note — unlinked.
8. Reported subcutaneous half-life values for GH-axis peptides derive from pre-2020 registration/PK studies; no single primary source is named in the prose for these figures — unlinked.
9. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov/9849822
10. Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov/16352683
11. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV. N Engl J Med. 2007. pubmed.ncbi.nlm.nih.gov/18057338
12. Somatropin Schedule 4 Part II controlled-drug status under the Misuse of Drugs Regulations 2001. UK regulatory position — unlinked.
13. Somatropin prescription-only medicine status; supply for non-medical human use is an offence under the Misuse of Drugs Act 1971. Regulatory position — unlinked.
14. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 (albumin-bound long-acting GHRH analog). J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov/16352683
15. MHRA position that a "research use only" label does not exempt a product from medicines regulation where presentation implies human use. Regulatory position — unlinked.